|
US4200750A
(en)
|
1977-01-07 |
1980-04-29 |
Westwood Pharmaceuticals Inc. |
4-Substituted imidazo [1,2-a]quinoxalines
|
|
US6069143A
(en)
|
1994-12-20 |
2000-05-30 |
Smithkline Beecham Corporation |
Fibrinogen receptor antagonists
|
|
WO2003061567A2
(en)
|
2002-01-18 |
2003-07-31 |
Merck & Co., Inc. |
Selective s1p1/edg1 receptor agonists
|
|
DE60330047D1
(en)
|
2002-01-18 |
2009-12-24 |
Merck & Co Inc |
"n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
|
|
AU2003207567B2
(en)
|
2002-01-18 |
2008-01-24 |
Merck Sharp & Dohme Corp. |
Edg receptor agonists
|
|
EP1482895A4
(en)
|
2002-03-01 |
2005-04-27 |
Merck & Co Inc |
AMINO ALKYL PHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS
|
|
AU2003276043A1
(en)
|
2002-06-17 |
2003-12-31 |
Merck & Co., Inc. |
1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
|
|
EP1625123A4
(en)
*
|
2003-05-15 |
2007-08-29 |
Merck & Co Inc |
3- (2-AMINO-1-AZACYCLYL) -5-ARYL-1,2,4-OXADIAZOLE AS S1P RECEPTOR AGONISTS
|
|
EP2644195A1
(en)
|
2003-05-19 |
2013-10-02 |
Irm Llc |
Immunosuppressant Compounds and Compositions
|
|
CA2539438A1
(en)
*
|
2003-10-01 |
2005-04-14 |
Merck And Co., Inc. |
3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
|
|
JP4773972B2
(ja)
|
2003-12-17 |
2011-09-14 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Ｓ１Ｐ（Ｅｄｇ）受容体作働薬としての（３，４−ジ置換）プロパンカルボン酸
|
|
TW200538433A
(en)
|
2004-02-24 |
2005-12-01 |
Irm Llc |
Immunosuppressant compounds and compositiions
|
|
WO2006047195A2
(en)
|
2004-10-22 |
2006-05-04 |
Merck & Co., Inc. |
2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
|
|
NZ562561A
(en)
|
2005-03-23 |
2010-11-26 |
Actelion Pharmaceuticals Ltd |
Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
|
|
TW200642683A
(en)
|
2005-04-22 |
2006-12-16 |
Sankyo Co |
Heterocyclic compound
|
|
JP2008545767A
(ja)
|
2005-06-08 |
2008-12-18 |
ノバルティス アクチエンゲゼルシャフト |
多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用
|
|
US20090221547A1
(en)
|
2005-08-23 |
2009-09-03 |
Irm Llc |
Immunosuppressant Compounds and Compositions
|
|
WO2007088450A2
(en)
|
2006-02-01 |
2007-08-09 |
Pfizer Products Inc. |
Chromane antagonist of the h-3 receptor
|
|
EP2010524A2
(en)
|
2006-03-21 |
2009-01-07 |
Epix Delaware, Inc. |
S1p receptor modulating compounds
|
|
CA2648303C
(en)
|
2006-04-03 |
2014-07-15 |
Astellas Pharma Inc. |
5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists
|
|
JP2009269819A
(ja)
|
2006-08-25 |
2009-11-19 |
Asahi Kasei Pharma Kk |
アミン化合物
|
|
US8288554B2
(en)
|
2006-09-08 |
2012-10-16 |
Actelion Pharmaceuticals Ltd. |
Pyridin-3-yl derivatives as immunomodulating agents
|
|
GB0625648D0
(en)
|
2006-12-21 |
2007-01-31 |
Glaxo Group Ltd |
Compounds
|
|
MX2009009597A
(es)
|
2007-03-16 |
2009-09-16 |
Actelion Pharmaceuticals Ltd |
Derivados de amino-piridina como agonistas del receptor s1p1/edg1.
|
|
CA2696863C
(en)
|
2007-10-04 |
2016-10-18 |
Anna Quattropani |
Oxadiazole derivatives
|
|
BRPI0818804A2
(pt)
|
2007-11-01 |
2015-04-22 |
Actelion Pharmaceuticals Ltd |
Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
|
|
GB0725105D0
(en)
|
2007-12-21 |
2008-01-30 |
Glaxo Group Ltd |
Compounds
|
|
US20090298894A1
(en)
*
|
2008-04-21 |
2009-12-03 |
Asahi Kasei Pharma Corporation |
Amino acid compounds
|
|
CN102245602B
(zh)
|
2008-12-18 |
2014-09-10 |
默克雪兰诺有限公司 |
用于治疗多发性硬化症的与恶二唑稠合的杂环衍生物
|
|
EP2202232A1
(en)
*
|
2008-12-26 |
2010-06-30 |
Laboratorios Almirall, S.A. |
1,2,4-oxadiazole derivatives and their therapeutic use
|
|
EP2210890A1
(en)
*
|
2009-01-19 |
2010-07-28 |
Almirall, S.A. |
Oxadiazole derivatives as S1P1 receptor agonists
|
|
JP2012515787A
(ja)
|
2009-01-23 |
2012-07-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
|
|
JP2012515789A
(ja)
*
|
2009-01-23 |
2012-07-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
スフィンゴシン−１−リン酸アゴニストとしてのピラゾール−１，２，４−オキサジアゾール誘導体
|
|
EP2389377B1
(en)
|
2009-01-23 |
2014-07-16 |
Bristol-Myers Squibb Company |
Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
|
|
US8399451B2
(en)
|
2009-08-07 |
2013-03-19 |
Bristol-Myers Squibb Company |
Heterocyclic compounds
|
|
EP2493866A1
(en)
|
2009-10-29 |
2012-09-05 |
Bristol-Myers Squibb Company |
Tricyclic heterocyclic compounds
|
|
WO2011133734A1
(en)
|
2010-04-23 |
2011-10-27 |
Bristol-Myers Squibb Company |
4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
|
|
ES2539256T3
(es)
|
2010-07-20 |
2015-06-29 |
Bristol-Myers Squibb Company |
Compuestos de 3-fenil-1,2,4-oxadiazol sustituidos
|
|
JP5869579B2
(ja)
|
2010-09-24 |
2016-02-24 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用
|